Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study

Archives of General Psychiatry

Volumn 64, Issue 6, 2007, Pages 689-697

  Perlis, Roy H ^a   Purcell, Shaun ^a   Fava, Maurizio ^a   Fagerness, Jesen ^a   Rush, A John ^b,c   Trivedi, Madhukar H ^b   Smoller, Jordan W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA; HYPNOTIC AGENT; SEDATIVE AGENT;

ANGER; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL IDEATION;

ADOLESCENT; ADULT; AGED; ANGER; CASE-CONTROL STUDIES; CITALOPRAM; COHORT STUDIES; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; SUICIDE;

EID: 34249943795     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.64.6.689     Document Type: Article

References (80)

1. Damluji NF, Ferguson JM. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol. 1988;8:347-349.
2. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147:207-210.
3. King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P, Scahill L. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry. 1991;30:179-186.
4. Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. N Engl J Med. 1991;324:420.
5. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide at-tempts by three patients: the role of akathisia. J Clin Psychiatry. 1991;52:491-493.
6. Wirshing WC, Van Putten T, Rosenberg J, Marder S, Ames D, Hicks-Gray T. Fluoxetine, akathisia, and suicidality: is there a causal connection? Arch Gen Psychiatry. 1992;49:580-581.
7. Meeting #34. In: US Food and Drug Administration Psychopharmacological Drugs Advisory Committee Meeting. Rockville, Md: Food and Drug Administration; 1991.
8. Pompili M, Tondo L, Baldessarini RJ. Suicidal risk emerging during antidepressant treatment: recognition and intervention. Clin Neuropsychiatry. 2005;2:66-72.
9. Beasley CM Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ. 1991;303: 685-692.
10. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160:790-792.
11. Storosum JG, van Zwieten BJ, van den Brink W, Gersons BP, Broekmans AW. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry. 2001;158:1271-1275.
12. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24:389-399.
13. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163:41-47.
14. Horwitz RI, Singer BH, Makuch RW, Viscoli CM. Can treatment that is helpful on average be harmful to some patients? a study of the conflicting information needs of clinical inquiry and drug regulation. J Clin Epidemiol. 1996;49:395-400.
15. Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry. 2003;64:123-133.
16. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292:338-343.
17. Class suicidality labeling language for antidepressants. http://www.fda.gov/cder/drug/antidepressants/PI_template.pdf. Accessed April 4, 2006.
18. Perlis RH, Beasley CM Jr, Wines JD Jr, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F, Strong RE, Rosenbaum JF, Fava M. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom. 2007;76:40-46.
19. Brent DA, Mann JJ. Family genetic studies, suicide, and suicidal behavior. Am J Med Genet C Semin Med Genet. 2005;133:13-24.
20. Fu Q, Heath AC, Bucholz KK, Nelson EC, Glowinski AL, Goldberg J, Lyons MJ, Tsuang MT, Jacob T, True MR, Eisen SA. A twin study of genetic and environmental influences on suicidality in men. Psychol Med. 2002;32:11-24.
21. Glowinski AL, Bucholz KK, Nelson EC, Fu Q, Madden PA, Reich W, Heath AC. Suicide attempts in an adolescent female twin sample. J Am Acad Child Adolesc Psychiatry. 2001;40:1300-1307.
22. Statham DJ, Heath AC, Madden PA, Bucholz KK, Bierut L, Dinwiddie SH, Slutske WS, Dunne MP, Martin NG. Suicidal behaviour: an epidemiological and genetic study. Psychol Med. 1998;28:839-855.
23. Yamada S, Yamamoto M, Ozawa H, Riederer P, Saito T. Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J Neural Transm. 2003;110:671-680.
24. Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet. 1998;352:1754-1755.
25. Koch JM, Kell S, Hinze-Selch D, Aldenhoff JB. Changes in CREB-phosphorylation during recovery from major depression. J Psychiatr Res. 2002;36:369-375.
26. Young LT, Bezchlibnyk YB, Chen B, Wang JF, MacQueen GM. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. Biol Psychiatry. 2004;55:570-577.
27. Dwivedi Y, Rao JS, Rizavi HS, Kotowski J, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60:273-282.
28. Odagaki Y, Garcia-Sevilla JA, Huguelet P, La Harpe R, Koyama T, Guimon J. Cyclic AMP-mediated signaling components are upregulated in the prefrontal cortex of depressed suicide victims. Brain Res. 2001;898:224-231.
29. Zubenko GS, Hughes HB III, Stiffler JS, Brechbiel A, Zubenko WN, Maher BS, Marazita ML. Sequence variations in CREB1 cosegregate with depressive disorders in women. Mol Psychiatry. 2003;8:611-618.
30. Manier DH, Shelton RC, Sulser F. Cross-talk between PKA and PKC in human fibroblasts: what are the pharmacotherapeutic implications? J Affect Disord. 2001; 65:275-279.
31. Perlis RH, Purcell S, Fagerness J, Cusin C, Yamaki L, Fava M, Smoller JW. Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder [published online ahead of print February 14, 2007]. Biol Psychiatry. doi:10.1016/j.biopsych.2006.10.034.
32. Conner KR, Meldrum S, Wieczorek WF, Duberstein PR, Welte JW. The association of irritability and impulsivity with suicidal ideation among 15- to 20-year-old males. Suicide Life Threat Behav. 2004;34:363-373.
33. Crook T, Raskin A, Davis D. Factors associated with attempted suicide among hospitalized depressed patients. Psychol Med. 1975;5:381-388.
34. Pendse B, Westrin A, Engstrom G. Temperament traits in seasonal affective disorder, suicide attempters with non-seasonal major depression and healthy controls. J Affect Disord. 1999;54:55-65.
35. Romanov K, Hatakka M, Keskinen E, Laaksonen H, Kaprio J, Rose RJ, Koskenvuo M. Self-reported hostility and suicidal acts, accidents, and accidental deaths: a prospective study of 21,443 adults aged 25 to 59. Psychosom Med. 1994;56:328-336.
36. Perlis RH, Fraguas R, Fava M, Trivedi MH, Luther JF, Wisniewski SR, Rush AJ. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry. 2005;66:159-166.
37. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457-494.
38. Rush AJ, Fava M, Wisniewski SR, Labori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PF, Biggs MM, Shores , Wilson K, Lebowitz BD, Ritz L, Niederehe G; STAR*D Investigators Group. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119-142.
39. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores , Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
41. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649-659.
42. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573-583.
43. Trivedi MH, Rush AJ, IbrahimHM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Korntein S, Manber R, Thase ME, Kocsis JH, Keller MB. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73-82.
44. Rush A, Carmody T, Reimitz P. The Inventory of Depressive Symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res. 2000;9:45-59.
45. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, Shores-Wilson K, Biggs MM, Woo A, Nierenberg AA, Fava M. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59:493-501.
46. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477-486.
47. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet. 2005;37:1217-1223.
48. Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim YM, Tsan G, Schaffner S, Kirov G, Jones I, Owen M, Craddock N, DePaulo JR, Lander ES. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol Psychiatry. 2002;7:579-593.
49. Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, Little DP, Strausberg R, Koester H, Cantor CR, Braun A. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time of-flight mass spectrometry. Proc Natl Acad Sci U S A. 2001;98:581-584.
50. Sham PC, Rijsdijk FV, Knight J, Makoff A, North B, Curtis D. Haplotype association analysis of discrete and continuous traits using mixture of regression models. Behav Genet. 2004;34:207-214.
51. Cordell HJ. Estimation and testing of genotype and haplotype effects in case-control studies: comparison of weighted regression and multiple imputation procedures. Genet Epidemiol. 2006;30:259-275.
52. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804-814.
53. Cautin RL, Overholser JC, Goetz P. Assessment of mode of anger expression in adolescent psychiatric inpatients. Adolescence. 2001;36:163-170.
54. Maiuro RD, O'Sullivan MJ, Michael MC, Vitaliano PP. Anger, hostility, and depression in assaultive vs. suicide-attempting males. J Clin Psychol. 1989;45:531-541.
55. Zubenko GS, Maher BS, Hughes HB III, Zubenko WN, Scott Stiffler J, Marazita ML. Genome-wide linkage survey for genetic loci that affect the risk of suicide attempts in families with recurrent, early-onset, major depression. Am J Med Genet B Neuropsychiatr Genet. 2004;129:47-54.
56. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter, II: suicidal behavior. Mol Psychiatry. 2003;8:646-653.
57. Lin PY, Tsai G. Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis. Biol Psychiatry. 2004;55:1023-1030.
58. De Luca V, Hlousek D, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. The interaction between TPH2 promoter haplotypes and clinical-demographic risk factors in suicide victims with major psychoses. Genes Brain Behav. 2006;5:107-110.
59. Stefulj J, Kubat M, Balija M, Skavic J, Jernej B. Variability of the tryptophan hydroxylase gene: study in victims of violent suicide. Psychiatry Res. 2005;134:67-73.
60. Zill P, Buttner A, Eisenmenger W, Moller HJ, Bondy B, Ackenheil M. Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol Psychiatry. 2004;56:581-586.
61. Abbar M, Courtet P, Bellivier F, Leboyer M, Boulenger JP, Castelhau D, Ferreira M, Lambercy C, Mouthon D, Paoloni , Giacobino A, Vessaz M, Malafosse A, Buresi C. Suicide attempts and the tryptophan hydroxylase gene. Mol Psychiatry. 2001;6:268-273.
62. Nielsen DA, Virkkunen M, Lappalainen J, Eggert M, Brown GL, Long JC, Godman D, Linnoila M. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry. 1998;55:593-602.
63. Arias B, Gasto C, Catalan R, Gutierrez B, Pintor L, Fananas L. The 5-HT(2A) receptor gene 102T/C polymorphism is associated with suicidal behavior in depressed patients. Am J Med Genet. 2001;105:801-804.
64. Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C, de Jonge S, Rupprecht R, Meyer H, Engel RR, Eisenmenger W, Ackenheil M. Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet. 2000;96:831-835.
65. Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet. 2000;96:56-60.
66. Du L, Faludi G, Palkovits M, Sotonyi P, Bakish D, Hardina PD. High activityrelated allele of MAO-A gene associated with depressed suicide in males. Neuroreport. 2002;13:1195-1198.
67. Lemonde S, Turecki G, Bakish D, Du L, Hardina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, Ou XM, Albert PR. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003;23:8788-8799.
68. Sherrin T, Heng KY, Zhu YZ, Tang YM, Lau G, Tan CH. Cholecystokinin-B receptor gene expression in cerebellum, pre-frontal cortex and cingulate gyrus and its association with suicide. Neurosci Lett. 2004;357:107-110.
69. Stefulj J, Buttner A, Skavic J, Zill P, Balija M, Eisenmenger W, Bondy B, Jernej B. Serotonin 1B (5HT-1B) receptor polymorphism (G861C) in suicide victims: association studies in German and Slavic population. Am J Med Genet B Neuropsychiatr Genet. 2004;127:48-50.
70. Tan EC, Chong SA, Chan AO, Tan CH. No evidence for association of the T102C polymorphism in the serotonin type 2A receptor with suicidal behavior in schizophrenia. Am J Med Genet. 2002;114:321-322.
71. Zubenko GS, Maher B, Hughes HB III, Zubenko WN, Stiffler JS, Kaplan BB, Marazita ML. Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression. Am J Med Genet B Neuropsychiatr Genet. 2003;123:1-18.
72. Laifenfeld D, Karry R, Klein E, Ben-Shachar D. Alterations in cell adhesion molecule L1 and functionally related genes in major depression: a postmortem study. Biol Psychiatry. 2005;57:716-725.
73. Reynolds WM. Psychometric characteristics of the Adult Suicidal Ideation Questionnaire in college students. J Pers Assess. 1991;56:289-307.
74. Beck AT, Brown GK, Steer RA. Psychometric characteristics of the Scale for Suicide Ideation with psychiatric outpatients. Behav Res Ther. 1997;35:1039-1046.
75. Brown GK. A review of suicide assessment measures for intervention research with adults and older adults. http://www.nimh.gov/suicideresearch/ adultsuicide.pdf. Accessed February 12, 2006.
76. Brown GK, Beck AT, Steer RA, Grisham JR. Risk factors for suicide in psychiatric outpatients: a 20-year prospective study. J Consult Clin Psychol. 2000;68:371-377.
77. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry. 1999;156:181-189.
78. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet. 2003;361:598-604.
79. Zubenko GS, Hughes HB III, Maher BS, Stiffler JS, Zubenko WN, Marazita ML. Genetic linkage of region containing the CREB1 gene to depressive disorders in women from families with recurrent, early-onset, major depression. Am J Med Genet. 2002;114:980-987.
80. Fava M, Nolan S, Kradin R, Rosenbaum J. Gender differences in hostility among depressed and medical outpatients. J Nerv Ment Dis. 1995;183:10-14.